Table 2.
Methodological quality prospective controlled studies
| Trial | A1 | B2 | C3 | C4 | C5 | D6 | D7 | E8 | F9 | F10 | F11a | F12 | Risk of bias | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FlexiCore® | Sasso et al. [53] | U | U | N | N | N | N | N | U | Y | U | NA | Y | 2/11 (high) |
| ProDisc® | Zigler et al. [52] | Y | U | N | N | N | N | N | Y | Y | U | NA | Y | 4/11 (high) |
| Charité® |
Blumenthal et al. [10] Guyer et al. [51] |
Y | Y | N | N | N | Y | Y | Y | Y | U | NA | Y | 7/11 (low)b |
| Y | Y | N | N | N | Y | N | Y | Y | U | NA | Y | 6/11 (low)c | ||
| Y | Y | N | N | N | N | U | Y | Y | U | NA | Y | 5/11 (high)d |
U unsure, Y yes, N no, NA not applicable
aCriteria 11 was scored
bFor overall measures, 2 year follow-up
cFor VAS en ODI outcome, 2 year follow-up
dFor 5 year follow-up